


## REMARKS

### Election/Restrictions

In response to the Restriction Requirement dated December 11, 2007, Applicants elect Group I, claims 1-8 drawn to methods for the treatment and/or prevention of neurological and vascular disorders related to beta-amyloid generation and/or aggregation comprising administering an inhibitor.

For the species, we designate Compound (I) disclosed on page 6 of the specification, namely: 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide having the formula I




Further from Claim 1, Applicants designate the species c-Kit from the list in claim 1.

From claim 3, Applicants designate the compound 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide.

With regard to Claim 6, Applicants designate the disease being Alzheimer's.

Respectfully submitted,



Lydia T. McNally  
Attorney for Applicant  
Reg. No. 36,214

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7898  
Date: February 4, 2008